Biotech Values

[DewDiligence]

FDA advisory panel endorses MRK’s antiplatelet drug, Vorapaxar, by 10-1 vote:

http://in.reuters.com/article/2014/01/15/us-merck-vorapaxar-idINBREA0E1KV20140115

For Vorapaxar, which was once considered the top commercial prospect in Schering-Plough’s late-stage pipeline, success has been a long time coming, and the potential approved indication will be much narrower than originally hoped.

If approved, the brand name will be Zontivity (not bad, IMO).